Trial Profile
Efficacy and Safety of OctaplasLG Administration vs. Crystalloids (Standard) in Patients With Septic Shock - a Randomized, Controlled, Open-label Investigator-initiated Pilot Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Plasma (Primary)
- Indications Septic shock
- Focus Pharmacodynamics
- Acronyms VIPER-SEPSIS
- 29 Nov 2016 Status changed from recruiting to discontinued.
- 25 Aug 2016 New source identified and integrated (ClinicalTrials.gov; NCT02875236)
- 30 May 2016 New trial record